These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30238350)

  • 1. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.
    Ciesielski MJ; Bu Y; Munich SA; Teegarden P; Smolinski MP; Clements JL; Lau JYN; Hangauer DG; Fenstermaker RA
    J Neurooncol; 2018 Dec; 140(3):519-527. PubMed ID: 30238350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).
    Smolinski MP; Bu Y; Clements J; Gelman IH; Hegab T; Cutler DL; Fang JWS; Fetterly G; Kwan R; Barnett A; Lau JYN; Hangauer DG
    J Med Chem; 2018 Jun; 61(11):4704-4719. PubMed ID: 29617135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.
    Cherry AE; Haas BR; Naydenov AV; Fung S; Xu C; Swinney K; Wagenbach M; Freeling J; Canton DA; Coy J; Horne EA; Rickman B; Vicente JJ; Scott JD; Ho RJ; Liggitt D; Wordeman L; Stella N
    Mol Cancer Ther; 2016 Sep; 15(9):2018-29. PubMed ID: 27325686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
    Naing A; Cohen R; Dy GK; Hong DS; Dyster L; Hangauer DG; Kwan R; Fetterly G; Kurzrock R; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):967-73. PubMed ID: 23361621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
    Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
    Antonarakis ES; Heath EI; Posadas EM; Yu EY; Harrison MR; Bruce JY; Cho SY; Wilding GE; Fetterly GJ; Hangauer DG; Kwan MF; Dyster LM; Carducci MA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):883-92. PubMed ID: 23314737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.
    Boumendjel A; McLeer-Florin A; Champelovier P; Allegro D; Muhammad D; Souard F; Derouazi M; Peyrot V; Toussaint B; Boutonnat J
    BMC Cancer; 2009 Jul; 9():242. PubMed ID: 19619277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
    Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SRC and tubulin in mucinous ovarian carcinoma.
    Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK
    Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure.
    Wang L; Zheng Y; Li D; Yang J; Lei L; Yan W; Zheng W; Tang M; Shi M; Zhang R; Cai X; Ni H; Ma X; Li N; Hong F; Ye H; Chen L
    J Med Chem; 2021 Jun; 64(12):8127-8141. PubMed ID: 34081857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
    Katsetos CD; Draber P; Kavallaris M
    Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.
    De Witt M; Gamble A; Hanson D; Markowitz D; Powell C; Al Dimassi S; Atlas M; Boockvar J; Ruggieri R; Symons M
    Mol Med; 2017 Apr; 23():50-56. PubMed ID: 28386621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
    BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
    Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
    Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
    Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
    Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evodiamine Prevents Glioma Growth, Induces Glioblastoma Cell Apoptosis and Cell Cycle Arrest through JNK Activation.
    Wu WS; Chien CC; Liu KH; Chen YC; Chiu WT
    Am J Chin Med; 2017; 45(4):879-899. PubMed ID: 28514905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy.
    Yang ZZ; Gao W; Liu YJ; Pang N; Qi XR
    Mol Pharm; 2017 Apr; 14(4):1012-1022. PubMed ID: 28252970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.